目的 探讨复方垂盆草胶囊联合替富马酸替诺福韦二吡呋酯片治疗慢性乙型病毒性肝炎的临床疗效。方法 选取2016年9月-2017年9月在儋州市人民医院治疗的慢性乙型病毒性肝炎患者96例，随机分为对照组（48例）和治疗组（48例）。对照组口服富马酸替诺福韦二吡呋酯片，300 mg/次，1次/d；治疗组在对照组基础上口服复方垂盆草胶囊，4粒/次，3次/d。两组均治疗12周。观察两组患者临床疗效，同时比较治疗前后两组患者肝功能、肝纤维化指标、体液免疫指标、T淋巴细胞亚群水平。结果 治疗后，对照组临床有效率为81.25%，显著低于治疗组的97.92%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者丙氨酸转氨酶（ALT）、门冬氨酸转氨酶（AST）、总胆红素（TBIL）水平均显著降低（P<0.05），且治疗组患者肝功能指标水平明显低于对照组（P<0.05）。治疗后，两组患者透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原肽（PC-Ⅲ）、Ⅳ胶原蛋白（Ⅳ-C）水平均显著降低（P<0.05），且治疗组患者上述肝纤维化指标明显低于对照组（P<0.05）。治疗后，两组患者IL-2和IL-21水平均显著升高（P<0.05），IL-17和IL-22水平显著降低（P<0.05），且治疗组这些体液免疫指标治疗后水平明显优于对照组（P<0.05）。治疗后，两组CD3⁺、CD4⁺、CD4⁺/CD8⁺水平均显著增高（P<0.05），且CD8⁺水平显著降低（P<0.05），同时治疗后治疗组T淋巴细胞亚群水平明显优于对照组（P<0.05）。结论 复方垂盆草胶囊联合替富马酸替诺福韦二吡呋酯治疗慢性乙型病毒性肝炎可有效改善患者肝功能，提高机体免疫力，预防肝纤维化，具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacy of Compound Chuipencao Capsules combined with tenofovir disoproxil in treatment of chronic hepatitis B. Methods Patients (96 cases) with chronic hepatitis B in Danzhou People's Hospital from September 2016 to September 2017 were randomly divided into control (48 cases) and treatment (48 cases) groups. Patients in the control group were po administered with Tenofovir Disoproxil Fumarate Tablets, 300 mg/time, once daily. Patients in the treatment group were po administered with Compound Chuipencao Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, the liver function, the liver fibrosis indexes, humoral immune indexes, and level of T lymphocyte subsets in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.25%, which was significantly lower than 97.92% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the ALT, AST and TBIL levels in two groups were significantly decreased (P<0.05), and these liver function indexes levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the HA, LN, PC-Ⅲ, and Ⅳ-C levels in two groups were significantly decreased (P<0.05), and these liver fibrosis indexes levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the IL-2 and IL-21 levels in two groups were significantly increased (P<0.05), but IL-17 and IL-22 levels were significantly decreased (P<0.05), and the humoral immune indexes in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the CD3⁺, CD4⁺ and CD4⁺/CD8⁺ levels in two groups were significantly increased (P<0.05), but CD8⁺ levels were significantly decreased (P<0.05), and the level of T lymphocyte subsets in the treatment group after treatment was significantly better than those in the control group (P<0.05). Conclusion Compound Chuipencao Capsules combined with tenofovir disoproxil in treatment of chronic hepatitis B can improve liver function, immunity and prevent liver fibrosis, which has a certain clinical application value.